Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
Key Points:
- Seawolf Therapeutics has raised $100 million from Versant Ventures, Eli Lilly, and other investors to develop non-viral gene delivery methods.
- The startup aims to overcome challenges associated with viral gene therapy, such as immune responses and dosing limitations.
- Sanofi has entered into a partnership with Seawolf Therapeutics, supporting its innovative approach.
- Current viral gene therapies are effective but limited by single-dose administration and potential serious side effects at high doses.